Medical device news covering implants, diagnostics, recalls, FDA clearances, and medtech company performance.
The article argues that low-energy shock wave therapy for erectile dysfunction is gaining popularity in the United States despite limited evidence of long-term benefits and lack of FDA approval. It highlights the treatment's potential to improve blood flow while noting skepticism from leading physician groups regarding its efficacy.
A senior UK coroner is calling for baby monitors to have their volume permanently locked to loud levels after an infant with Down's Syndrome died because his alarm was turned down too low. The recommendation follows an inquest into the death of Ismaeel Islam, whose deteriorating condition went unnoticed by nurses for thirty minutes due to the inaudible alarm.
The volume of recalled products in the United States reached 941.2 million units in the first half of 2026, putting the annual total on pace to exceed one billion for the fourth time in 15 years. Pharmaceutical recalls increased 914% year-over-year to 471.6 million units, while medical device recalls rose 516.8% to 313.1 million units.
The article analyzes the strategic partnership between Abbott Laboratories and MiniMed Group, contrasting Abbott's diversified financial strength with MiniMed's specialized growth potential in diabetes technology. It evaluates bull and bear cases for both companies based on recent product integrations and earnings data.
The author investigates the efficacy of consumer vagus nerve stimulators, testing devices personally and consulting medical experts. While acknowledging the nerve's role in relaxation, the piece suggests these gadgets offer minimal benefit beyond placebo effects compared to established medical treatments.
The Successful Investor argues that medical technology stocks offer sustainable dividends despite near-term underperformance. Citing an aging population and global middle-class growth, the article applies a proprietary sustainability rating system to identify top dividend payers in Canada and the US.
California-based MaxQ Medical secured $31.5 million in Series A funding led by Olympus Innovation Ventures, Atlantic Blue Ventures, and S3 Ventures. The company will use the capital to expand its team and advance clinical programs for its transurethral platform combining ultrasound imaging with tissue-selective therapy for benign prostate hyperplasia.